Evgeniy A. Burtsev

Evgeniy A. Burtsev

Auto-generated profile, based on publicly available information

Evgeniy A. Burtsev

Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
DEDmitry Evseev
Dmitry Evseev
DODaria Osipova
Daria Osipova
IKIrina Kalinina
Irina Kalinina
ERElena Raykina
Elena Raykina
AIAnna Ignatova
Anna Ignatova
MMMichael Maschan
Michael Maschan
Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in LCH led to a targeted approach. However, targeted therapy cannot cure the disease, and cessation leads to quick relapses. Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission. Nineteen children were enrolled in the study: 13 were RO-positive (RO+) and 6 RO-negative (RO–). Five patients received the therapy upfront, whereas the other 14 received it as a second or third line. The protocol starts with 28 days of vemurafenib (20 mg/kg), which is followed by 3 courses of Ara-C and 2-CdA (100 mg/m2 every 12 h, 6 mg/m2 per day, days 1-5) with concomitant vemurafenib therapy. After that, vemurafenib therapy was stopped, and 3 courses of mono 2-CdA followed. All patients rapidly responded to vemurafenib: the median disease activity score decreased from 13 to 2 points in the RO+ group and from 4.5 to 0 points in the RO– group on day 28. All patients except 1 received complete protocol treatment, and 15 of them did not have disease progression. The 2-year reactivation/progression-free survival (RFS) for RO+ was 76.9% with a median follow-up of 21 months and 83.3% with a median follow-up of 29 months for RO–. Overall survival is 100%. Importantly, 1 patient experienced secondary myelodysplastic syndrome after 14 months from vemurafenib cessation. Our study demonstrates that combined vemurafenib plus 2-CdA and Ara-C is effective in a cohort of children with LCH, and the toxicity is manageable. This trial is registered at www.clinicaltrials.gov as NCT03585686.

25 February 2023 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
EBEvgeniy A. Burtsev
Evgeniy A. Burtsev
GBGleb O. Bronin
Gleb O. Bronin
Relevant information on Langerhans cell histiocytosis development and course in children is presented. The current concepts of disease pathogenesis, principles of its severity evaluation, patients stratification into risk groups, as well as of clinical course features are described. Modern approaches to the disease treatment via targeted therapy are summarized and analyzed.

8 November 2022 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
EBE. A. Burtsev
E. A. Burtsev
GBG. O. Bronin
G. O. Bronin
Background. There are increasing data of targeted therapy efficacy of different types of Langerhans cell histiocytosis (LCH) with inhibitors of BRAF-specific serin-threonine kinase (BRAF-inhibitors) in cases with BRAF V600E mutation published last years. At the same time there are no published data of use of inhibitors of MAPK/ERK pathway (MEK-inhibitors) in pediatric patients with BRAF-negative forms of LCH.Purpose of the study is to evaluate efficacy and safety of MEK-inhibitor (cobimetinib) in eight pediatric BRAF V600E-negative refractory LCH patients.Materials and methods. The study included 8 children with various forms of LCH. All patients received therapy according to the LCH-IV protocol and were diagnosed with progression of LCH during or after termination of the treatment. The response to the therapy was assessed in accordance with the international scale Response Evaluation Criteria in Solid Tumors (RECIST v.1.1). The assessment of the toxicity was performed in accordance with the international scale of Common Terminology Criteria for Adverse Events (CTCAE v.5.0).Results. Complete response was not achieved in any patient. Partial response was established in 5 cases. One patient was diagnosed with disease progression in three months after termination of the therapy. The incidence of adverse events was high.Conclusion. Cobimetinib therapy is effective in BRAF V600E-negative refractory pediatric LCH patients. The response to the treatment can be delayed. All cases of the toxicity were dose depended and successfully resolved after dose correction. Further research is needed to define duration of treatment and optimal dosage.

24 June 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GSG. Z. Seregin
G. Z. Seregin
YBYu. A. Bespyatykh
Yu. A. Bespyatykh
AGA. V. Gospodarik
A. V. Gospodarik
MKMikhail Kirillov
Mikhail Kirillov
LOLarisa Ogneva
Larisa Ogneva
ЮБЮ. А. Беспятых
Ю. А. Беспятых
Fecal microbiota transplantation (FMT) is a promising therapy for a variety of diseases involving the gastrointestinal (GI) tract. The purpose of our study is to evaluate the effectiveness of FMT for the treatment of different GI complications after allogenic hematopoietic stem cell transplantation (steroid-refractory and steroid-dependent graft versus host disease (SR/ SD GVHD) and infectious enterocolitis) in children from 1.5 to 18 years old. The study was approved by the Local Ethics Committee of the Morozov Children's Clinical Hospital of the Department of Health of Moscow (No. 176 dated 24.05.2022). The patients' parents gave their informed consent to the participation of their children in the study and the publication of the study results. SR/SD GVHD group included 14 patients and GI infections group – 11 patients. In total, 38 FMTs were performed. Eleven children underwent repeated FMTs due to the lack of effect after the first FMT. The resolution of diarrhea followed by the withdrawal of corticosteroids was recorded in 11 out of 14 patients with SR/SD GVHD. Ten out of 11 patients with GI infections also achieved relief of diarrhea. The clinical effect correlated with changes in the microbiome structure: for both groups of patients, the median proportion of normal microbiota before FMT was 6%, after FMT – 92% (p = 0.043). The median number of different taxa for both groups of patients before and after FMT were 3 and 10 taxa, respectively (p = 0.0016).

14 February 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DOD. S. Osipova
D. S. Osipova
ERE. V. Raykina
E. V. Raykina
ELE. I. Lyudovskikh
E. I. Lyudovskikh
DED. A. Evseev
D. A. Evseev
IKI. I. Kalinina
I. I. Kalinina
MMMichael Maschan
Michael Maschan
This article discusses the potential of droplet digital polymerase chain reaction (PCR) for the diagnostic detection and monitoring of the allelic load of the BRAF V600E mutation in circulating cell-free DNA and myeloid progenitor cell population in the bone marrow of patients with Langerhans cell histiocytosis (LCH). Droplet digital PCR may serve as a useful tool for the monitoring of minimal residual disease and improve our understanding of the pathogenesis of Langerhans cells histiocytosis. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.

15 April 2023 in Russian Journal of Child Neurology
Verified
Journal Article
Open access
PDF file
NBN. V. Bronina
N. V. Bronina
ISI. O. Schederkina
I. O. Schederkina
BKB. M. Kurmanov
B. M. Kurmanov
EBE. A. Burtsev
E. A. Burtsev
MNM. V. Natrusova
M. V. Natrusova
GBG. O. Bronin
G. O. Bronin
Glutamic acid decarboxylase (GAD) is an intracellular enzyme expressed in brain neurons and insulin-secreting β-cells of the pancreas. Anti-GAD-anitibodies are associated with type 1 diabetes mellitus, limbic encephalitis, cerebellar ataxia, temporal autoimmune epilepsy, and rigid man syndrome. We present a rare clinical case of anti-GAD-anitibodies- associated immune encephalitis in a child with beta-thalassemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT).A 3-year-old boy diagnosed with beta-thalassemia underwent allo-HSCT from a 9/10 compatible unrelated donor. The macrophage activation syndrome occurred during the early post-transplantation period. The seizure with a focal onset happened on day +65. The cytotoxic edema in the region of the left hippocampus without signs of accumulation of a contrast agent was revealed at the magnetic resonance imaging of the brain. Pleocytosis, increase in protein levels, infection and antibodies to receptors and synaptic proteins of neurons were not detected at the analysis of cerebrospinal fluid. A positive titer to anti-GAD-anitibodies was detected in the blood – 315.82 IU/ml (the norm is up to 10 IU/ml). The child was treated with cyclophosphamide 750 mg/m2, rituximab 375 mg/m2, and tocilizumab 8 mg/kg. The cytotoxic edema in the left hippocampus regressed at the control magnetic resonance imaging on day +117.Infectious, immune and toxic agents can cause the damage of central nervous system in patients after allo-HSCT. The mechanism of immune damage to the central nervous system S in such patients is still being studied and may be different: expansion of autoreactive lymphocytes due to failure of T-cell regulation due to chemo- or immunosuppressive therapy, “passenger lymphocyte” syndrome, violation of T-cell regulation due to the course of infectious complications and acute graft versus host disease.In a series of diagnostic searches in patients with central nervous system lesions after allo-HSCT, it is necessary to include immune damage to the nervous system. Diagnosis of such conditions is a difficult task due to comorbidity and multicomponent accompanying therapy, including immunosuppressive therapy, administered to patients.